

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?
deltoid in 23G gluteal 1 1/2 in 22G regardless of weight
2. Name the most common side effects a patient may experience when taking Invega Sustenna®.
injection site reactions, somnolence/sedation, dizziness, akathisia, extrapyramidal disorder
3. What black box warning is associated with this medication?
increased mortality in elderly patients w dementia-related psychosis
4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?
day 1: 234mg day 8: 156mg
5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?
117mg
6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?
deltoid
7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?
day 1: 156mg day 8: 117mg

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

monthly maintenance dose 78mg

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

tolerability should be established with oral paliperidone or oral risperidone prior to initiating treatment with invega

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

proper hand hygiene
open syringes/needles without touching hub
clean vial top & injection site with alcohol pad

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

protects patient autonomy (7 rights), ensures ethical practice, & prevents med waste because if patient declines after med is drawn up the dose must be discarded